Arcus Biosciences, Inc. financial data

Symbol
RCUS on NYSE
Industry
Pharmaceutical Preparations
Location
3928 Point Eden Way, Hayward, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 501 % +0.24%
Return On Equity -47.3 % +17.2%
Return On Assets -23.2 % +10.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 106M shares +16.4%
Common Stock, Shares, Outstanding 92.2M shares +22.1%
Entity Public Float 825M USD -22.7%
Weighted Average Number of Shares Outstanding, Basic 90.1M shares +21.8%
Weighted Average Number of Shares Outstanding, Diluted 90.1M shares +21.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 51M USD +37.8%
Research and Development Expense 448M USD +31.8%
General and Administrative Expense 120M USD +2.56%
Operating Income (Loss) -330M USD +2.94%
Nonoperating Income (Expense) 48M USD +23.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -282M USD +6.31%
Income Tax Expense (Benefit) 1M USD -83.3%
Net Income (Loss) Attributable to Parent -283M USD +7.82%
Earnings Per Share, Basic -3.14 USD/shares +24.3%
Earnings Per Share, Diluted -3.14 USD/shares +24.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 150M USD +18.1%
Assets, Current 1.02B USD +22.3%
Property, Plant and Equipment, Net 47M USD -7.84%
Operating Lease, Right-of-Use Asset 65M USD -29.3%
Other Assets, Noncurrent 73M USD -31.1%
Assets 1.15B USD +5.02%
Accounts Payable, Current 18M USD +5.88%
Employee-related Liabilities, Current 31M USD +19.2%
Contract with Customer, Liability, Current 85M USD -6.59%
Liabilities, Current 226M USD +22.8%
Contract with Customer, Liability, Noncurrent 234M USD -23.8%
Operating Lease, Liability, Noncurrent 99M USD -10%
Other Liabilities, Noncurrent 157M USD +10.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1M USD
Retained Earnings (Accumulated Deficit) -1.13B USD -33.3%
Stockholders' Equity Attributable to Parent 485M USD +4.98%
Liabilities and Equity 1.15B USD +5.02%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2M USD +98%
Net Cash Provided by (Used in) Financing Activities 229M USD +22800%
Net Cash Provided by (Used in) Investing Activities -169M USD -231%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 92.2M shares +22.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 58M USD +81.3%
Deferred Tax Assets, Valuation Allowance 316M USD +35.6%
Deferred Tax Assets, Gross 330M USD +30.4%
Operating Lease, Liability 111M USD -8.26%
Payments to Acquire Property, Plant, and Equipment 4M USD +33.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -283M USD +5.67%
Lessee, Operating Lease, Liability, to be Paid 133M USD -10.7%
Property, Plant and Equipment, Gross 88M USD +7.32%
Operating Lease, Liability, Current 12M USD +9.09%
Lessee, Operating Lease, Liability, to be Paid, Year Two 18M USD +5.88%
Lessee, Operating Lease, Liability, to be Paid, Year One 17M USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 22M USD -21.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 18M USD +5.88%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 19M USD +46.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 19M USD +5.56%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 76M USD +4.11%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%